<DOC>
	<DOC>NCT02826018</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALN-HBV in healthy adult volunteers and patients with chronic hepatitis B virus (HBV) infection. In addition, the study will assess antiviral efficacy of ALN-HBV in patients with HBV.</brief_summary>
	<brief_title>A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection</brief_title>
	<detailed_description>The study has 3 parts. Part A is a single ascending dose (SAD) study in healthy volunteers. Part B is a single ascending dose study (SAD) in patients with HBV infection. Part C is a multiple ascending dose study (MAD) in patients with HBV infection.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<criteria>All subjects: 18 to 65 years inclusive Women of childbearing potential must have a negative pregnancy test, cannot be breast feeding, and must be willing to use a highly effective method of contraception Agrees not to donate blood during the duration of the study Willing to comply with the study requirements and to provide written informed consent Additional inclusion criteria for patients with HBV infection: Body mass index (BMI) â‰¥18.0 kg/m2 Must be on a stable regimen of entecavir or tenofovir All subjects: Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the subject at significant risk Subjects with a history of serious mental illness Active infection with human immunodeficiency virus (HIV) infection, hepatitis A virus (HAV), or hepatitis C virus (HCV) infection and/or a history of delta virus hepatitis Known hypersensitivity or contraindication to any medication or history of allergic reaction to an oligonucleotide or Nacetylgalactosamine (GalNAc) Additional exclusion criteria for healthy volunteers: Evidence of liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>Hepatitis B, Chronic</keyword>
	<keyword>Hepatitis B Infection</keyword>
	<keyword>HBV</keyword>
</DOC>